Finally, we evaluated the clinical relevance of the three proteins CDK6, p-CDK2 and cyclin E1, found to be upregulated in our AI-resistant and combined CDK4/6 and fulvestrant-resistant BC cells. This evidence concerns the gene CDK4 and breast cancer.